

**Biomedical Imaging Research Core (BICOR)**

**Intake Form, Listed Radiotracer**

**Project Information**

- Title of Project \_\_\_\_\_
- Project acronym \_\_\_\_\_
- Project start date \_\_\_\_\_
- Project end date \_\_\_\_\_

**Principal Investigator**

- Name \_\_\_\_\_
- Address \_\_\_\_\_  
\_\_\_\_\_
- Email \_\_\_\_\_
- Mass DPH, Controlled Substance License Number \_\_\_\_\_

**Account information**

- Project number \_\_\_\_\_
- Partner's PeopleSoft Account Number \_\_\_\_\_
- Account end date \_\_\_\_\_
- Contact for invoicing if not PI \_\_\_\_\_
- Invoice address \_\_\_\_\_  
\_\_\_\_\_
- Invoice email \_\_\_\_\_
- Source of funding \_\_\_\_\_

**Tracer Information**

- Radioisotope \_\_\_\_\_
- Compound \_\_\_\_\_
- Human use\* \_\_\_\_\_
- Required strength \_\_\_\_\_ - mCi
- Required concentration \_\_\_\_\_ -mCi/mL
- Number of doses \_\_\_\_\_

\*In the case of investigational radioactive drugs for human use, the nuclear pharmacy requires an investigator's protocol for the preparation of radioactive drugs (if applicable), a copy of the Human Use Committee Approval, a copy of the approved patient consent form, and a letter from the sponsor indicating that the physician requesting the radioactive drug is a qualified investigator and the PI's Mass DPH Controlled Substance License number.